Eastern equine encephalitis virus: Pathogenesis, immune response, and clinical manifestations.

Bhumika Parashar, Rishabha Malviya, Sathvik Belagodu Sridhar, Tarun Wadhwa, Sirajunisa Talath, Javedh Shareef
Author Information
  1. Bhumika Parashar: Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida 201310, Uttar Pradesh, India.
  2. Rishabha Malviya: Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida 201310, Uttar Pradesh, India.
  3. Sathvik Belagodu Sridhar: RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
  4. Tarun Wadhwa: RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
  5. Sirajunisa Talath: RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
  6. Javedh Shareef: RAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.

Abstract

Eastern equine encephalitis virus (EEEV) is a lethal transmitted by mosquitoes that primarily cycles between birds. Although rare, infections in humans and horses are associated with high mortality rates and severe neurological effects. Climate change appears to be increasing the spread of this virus. This study aims to provide a comprehensive analysis of EEEV, including its transmission dynamics, pathogenesis, induced host immune response, and long-term impacts on survivors. It also highlights the virus's unique immune evasion strategies that complicate disease management and contribute to severe clinical outcomes, such as encephalitis with fever, convulsions, and coma. Survivors often face chronic cognitive, motor, and psychosocial impairments. Despite these significant public health risks, gaps remain in understanding the molecular mechanisms underlying immune evasion and the long-term neurological sequelae in survivors. By collating current knowledge, this review underscores the urgent need for the development of targeted vaccines and therapeutic interventions to mitigate the growing threat of EEEV, particularly in the context of climate change-driven geographical expansion.

Keywords

References

  1. PLoS Negl Trop Dis. 2016 Apr 06;10(4):e0004611 [PMID: 27050414]
  2. Mol Neurobiol. 2024 May;61(5):2881-2903 [PMID: 37946006]
  3. Immunol Res. 2012 Sep;53(1-3):136-47 [PMID: 22418724]
  4. Virology. 2000 Apr 25;270(1):111-23 [PMID: 10772984]
  5. Adv Virus Res. 1989;36:255-71 [PMID: 2544083]
  6. Nat Rev Rheumatol. 2012 May 08;8(7):420-9 [PMID: 22565316]
  7. MMWR Morb Mortal Wkly Rep. 2006 Jun 30;55(25):697-700 [PMID: 16810146]
  8. Neurology. 2006 Jan 10;66(1):75-80 [PMID: 16401850]
  9. J Infect Dis. 1962 Jan-Feb;110:80-97 [PMID: 13899188]
  10. Trends Microbiol. 2015 Jan;23(1):35-43 [PMID: 25449049]
  11. Emerg Infect Dis. 2015 Sep;21(9):1562-7 [PMID: 26295485]
  12. J Infect Dis. 2008 Jun 1;197(11):1585-93 [PMID: 18433328]
  13. Neurocrit Care. 2017 Dec;27(3):447-457 [PMID: 28741102]
  14. Environ Health Perspect. 2020 May;128(5):57007 [PMID: 32441995]
  15. J Virol. 2005 Jun;79(12):7597-608 [PMID: 15919912]
  16. Rev Sci Tech. 2015 Aug;34(2):491-501 [PMID: 26601451]
  17. Viruses. 2019 Aug 29;11(9): [PMID: 31470617]
  18. J Gen Virol. 2009 Aug;90(Pt 8):1836-1847 [PMID: 19369408]
  19. Parasit Vectors. 2015 Oct 09;8:516 [PMID: 26453283]
  20. Int J Mol Sci. 2018 Sep 18;19(9): [PMID: 30231586]
  21. J Virol. 2011 Jan;85(1):606-20 [PMID: 20962078]
  22. PLoS Pathog. 2024 Sep 27;20(9):e1012179 [PMID: 39331659]
  23. Front Cell Infect Microbiol. 2024 Aug 15;14:1421571 [PMID: 39211797]
  24. Virology. 2014 Nov;468-470:479-489 [PMID: 25261870]
  25. Handb Clin Neurol. 2014;123:417-32 [PMID: 25015497]
  26. PLoS Pathog. 2024 Mar 14;20(3):e1011794 [PMID: 38483968]
  27. Biomed Environ Sci. 2011 Feb;24(1):81-7 [PMID: 21440844]
  28. J Neurol Sci. 2024 Feb 15;457:122886 [PMID: 38278094]
  29. N Engl J Med. 1997 Jun 26;336(26):1867-74 [PMID: 9197215]
  30. BMJ Open. 2018 May 14;8(5):e015928 [PMID: 29764868]
  31. Vector Borne Zoonotic Dis. 2011 Jun;11(6):637-9 [PMID: 21254938]
  32. N Engl J Med. 2013 Aug 22;369(8):732-44 [PMID: 23964935]
  33. J Virol. 2013 Feb;87(3):1821-33 [PMID: 23192868]
  34. J Neuroinflammation. 2020 Aug 10;17(1):233 [PMID: 32778106]
  35. Front Microbiol. 2016 Jun 20;7:959 [PMID: 27379085]
  36. mBio. 2024 Jun 12;15(6):e0073624 [PMID: 38695564]
  37. Med Health R I. 2012 Jul;95(7):227-9 [PMID: 22928238]
  38. Adv Immunol. 2023;158:1-74 [PMID: 37453753]
  39. Infect Dis Now. 2022 Feb;52(1):1-6 [PMID: 34896660]
  40. Front Immunol. 2024 Jan 25;15:1287940 [PMID: 38343534]
  41. Cell Mol Immunol. 2021 Feb;18(2):250-258 [PMID: 33437050]
  42. J Neurol Sci. 2013 Feb 15;325(1-2):15-21 [PMID: 23260319]
  43. Virol J. 2011 Apr 29;8:197 [PMID: 21529366]
  44. J Clin Neurol. 2024 Jan;20(1):23-36 [PMID: 38179629]
  45. Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16053-8 [PMID: 25362048]
  46. J Virol. 2008 Nov;82(21):10634-46 [PMID: 18768986]
  47. Viruses. 2018 Feb 28;10(3): [PMID: 29495654]
  48. Virus Res. 2014 Aug 30;189:194-205 [PMID: 24905288]
  49. Medicine (Baltimore). 2024 Dec 27;103(52):e41170 [PMID: 39969305]
  50. Front Immunol. 2022 Sep 12;13:1005586 [PMID: 36172361]
  51. J Gen Virol. 2009 Aug;90(Pt 8):1848-1858 [PMID: 19403754]
  52. Infect Med (Beijing). 2024 Aug 13;3(3):100130 [PMID: 39309297]
  53. Vet Microbiol. 2010 Jan 27;140(3-4):281-6 [PMID: 19775836]
  54. J Exp Med. 2019 Oct 7;216(10):2282-2301 [PMID: 31337735]
  55. Int J Mol Sci. 2018 Oct 09;19(10): [PMID: 30304853]
  56. Can J Neurol Sci. 2024 Jan;51(1):40-49 [PMID: 36597285]
  57. Immunol Rev. 2008 Oct;225:27-45 [PMID: 18837774]
  58. Viruses. 2024 Feb 27;16(3): [PMID: 38543734]
  59. Nat Commun. 2024 Aug 2;15(1):6548 [PMID: 39095394]
  60. Virol J. 2009 Oct 23;6:170 [PMID: 19852817]
  61. PLoS One. 2014 Aug 12;9(8):e104708 [PMID: 25116127]
  62. N Engl J Med. 2019 Nov 21;381(21):1989-1992 [PMID: 31747726]
  63. Cerebellum. 2024 Aug;23(4):1411-1425 [PMID: 38165578]
  64. J Microbiol Immunol Infect. 2005 Dec;38(6):417-24 [PMID: 16341342]
  65. Vaccines (Basel). 2020 Jun 03;8(2): [PMID: 32503232]
  66. Acta Neuropathol. 2024 Jan 29;147(1):26 [PMID: 38286873]
  67. Arch Virol. 1995;140(12):2243-54 [PMID: 8572944]
  68. Soc Sci Med. 2014 Feb;103:76-83 [PMID: 24507913]
  69. J Mol Biol. 2014 Mar 20;426(6):1246-64 [PMID: 24316048]
  70. Clin Infect Dis. 2002 Aug 1;35(3):254-60 [PMID: 12115090]
  71. Neuroradiology. 2003 Feb;45(2):100-6 [PMID: 12592493]
  72. Handb Clin Neurol. 2014;123:225-47 [PMID: 25015488]
  73. J Virol. 2016 May 27;90(12):5785-96 [PMID: 27053560]
  74. J Virol. 2011 Oct;85(20):10682-90 [PMID: 21849461]
  75. Ann Glob Health. 2021 Oct 21;87(1):103 [PMID: 34722167]
  76. J Leukoc Biol. 2024 Sep 20;: [PMID: 39302155]
  77. Biochim Biophys Acta Gen Subj. 2024 Mar;1868(3):130558 [PMID: 38185238]
  78. Annu Rev Immunol. 2019 Apr 26;37:73-95 [PMID: 31026414]
  79. Cell Stem Cell. 2016 Nov 3;19(5):663-671 [PMID: 27524440]
  80. Cell Host Microbe. 2013 Apr 17;13(4):379-93 [PMID: 23601101]
  81. Neurology. 2007 Jul 10;69(2):156-65 [PMID: 17620548]
  82. J Exp Med. 2024 Sep 2;221(9): [PMID: 39042188]
  83. Curr Opin Virol. 2017 Apr;23:30-34 [PMID: 28288385]
  84. J Gen Virol. 2021 Aug;102(8): [PMID: 34435944]
  85. J Virol. 2002 Jan;76(1):392-6 [PMID: 11739703]
  86. J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):135-7 [PMID: 15608016]
  87. Neurol Clin Pract. 2021 Oct;11(5):e714-e721 [PMID: 34840888]
  88. Neuropsychol Rehabil. 2007 Aug-Oct;17(4-5):406-28 [PMID: 17676528]
  89. Cell Host Microbe. 2024 Apr 10;32(4):606-622.e8 [PMID: 38479396]
  90. Vector Borne Zoonotic Dis. 2024 Feb;24(2):118-121 [PMID: 37870590]
  91. Am J Pathol. 2005 Jan;166(1):159-71 [PMID: 15632009]
  92. Curr Opin Neurol. 2007 Jun;20(3):247-54 [PMID: 17495616]
  93. J Atten Disord. 2007 Nov;11(3):336-8; discussion 339-40 [PMID: 17932384]
  94. Curr Opin Virol. 2018 Feb;28:53-60 [PMID: 29175515]
  95. Virol J. 2015 Sep 29;12:152 [PMID: 26420265]
  96. J Med Chem. 2012 Apr 12;55(7):3535-45 [PMID: 22428985]
  97. J Proteome Res. 2024 Aug 2;23(8):3249-3268 [PMID: 38564653]
  98. Viruses. 2019 Mar 22;11(3): [PMID: 30909385]
  99. Environ Health Perspect. 2017 Jun 05;125(6):067001 [PMID: 28731409]
  100. Clin Infect Dis. 2012 May;54(10):1455-64 [PMID: 22460967]
  101. J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1044-54 [PMID: 1783914]
  102. Virology. 1995 Apr 20;208(2):662-71 [PMID: 7747437]
  103. ACS Infect Dis. 2024 Aug 9;10(8):2507-2524 [PMID: 38992989]
  104. Virology. 2009 Dec 5;395(1):121-32 [PMID: 19782381]
  105. J Neuroimmune Pharmacol. 2010 Sep;5(3):428-42 [PMID: 20652430]
  106. Dev Med Child Neurol. 2016 Nov;58(11):1108-1115 [PMID: 27422743]
  107. J Virol. 2010 Jan;84(2):1014-25 [PMID: 19889755]
  108. Vector Borne Zoonotic Dis. 2021 May;21(5):305-320 [PMID: 33332203]
  109. J Virol. 2005 Sep;79(17):11300-10 [PMID: 16103182]
  110. Nucleic Acids Res. 2018 Apr 20;46(7):3657-3670 [PMID: 29361131]

Word Cloud

Created with Highcharts 10.0.0immuneencephalitisEEEVevasionEasternequinevirussevereneurologicaltransmissionpathogenesisresponselong-termsurvivorsclinicalsequelaelethaltransmittedmosquitoesprimarilycyclesbirdsAlthoughrareinfectionshumanshorsesassociatedhighmortalityrateseffectsClimatechangeappearsincreasingspreadstudyaimsprovidecomprehensiveanalysisincludingdynamicsinducedhostimpactsalsohighlightsvirus'suniquestrategiescomplicatediseasemanagementcontributeoutcomesfeverconvulsionscomaSurvivorsoftenfacechroniccognitivemotorpsychosocialimpairmentsDespitesignificantpublichealthrisksgapsremainunderstandingmolecularmechanismsunderlyingcollatingcurrentknowledgereviewunderscoresurgentneeddevelopmenttargetedvaccinestherapeuticinterventionsmitigategrowingthreatparticularlycontextclimatechange-drivengeographicalexpansionvirus:PathogenesismanifestationsAlphavirusImmuneNeuroinflammationNeurologicalViral

Similar Articles

Cited By

No available data.